Jeito Capital leads €20 Million Investment in InnoSkel, a New Gene Therapy Company and leader in rare skeletal disorders
Share: Jeito Capital leads €20 Million Investment in InnoSkel, a New Gene Therapy Company and leader in rare skeletal disorders Jeito's third international investment in H2 2020, with deep and rapidly accelerating pipeline Therachon's Founder, Elvire Gouze, launches latest new gene therapy company in her field of excellence €20 million Series A financing, sees Jeito co-investing again with Vida Ventures Paris, France, 14 December 2020 – Jeito Capital ("Jeito"), a rapidly emerging independent investor dedicated to biotech and biopharma, today announces that it has led a €20 million Ser...